Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials.

Bruce IN, et al. Lupus Sci Med. 2023;10(1):e000761.

Safety and efficacy of belimumab in patients with lupus nephritis: open-label extension of BLISS-LN study.

Furie R, et al. Clin J Am Soc Nephrol. 2022;17(11):1620-1630.

Anifrolumab in lupus nephritis: results from second-year extension of a randomized phase II trial.

Jayne D, et al. Lupus Sci Med. 2023;10(2):e000910.

A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus.

Kalunian KC, et al. Arthritis Rheumatol. 2023;75(2):253-265. 

Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials.

Morand EF, et al. Lancet Rheum. 2022;4(4):E282-E292.

Trial of anifrolumab in active systemic lupus erythematosus.

Morand EF, et al. N Engl J Med. 2020;382(3):211-221.

Restrictive use of oral glucocorticoids in systemic lupus erythematosus and prevention of damage without worsening long-term disease control: an observational study.

Ruiz-Arruza I, et al. Arthritis Care Res. 2018;70(4):582-591.

Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus.

Wallace DJ, et al. Arthritis Rheumatol. 2019;71(7):1125-1134.